|
23. Maijs 2021|23:07 |
" It proved to have been a good decision never to do contract research with the cheapest external providers, but only with those with good reputations. This was true not only for drug substance and product, but toxicology studies, clinical, advisors, market assessment, legal and tax."
Nav briinums, ka peec padsmit gadiem kantorii ar skandalozu reputaaciju cilveeks noguris no bezgaliigaam mahinaacijaam un tiesu praavaam ("Pfizer fined $2.3 billion for illegal marketing ---Pfizer Agrees to Pay $23.85 Million to Resolve Allegations---Pfizer to pay £50m after deaths of Nigerian children---" sodu saraksts ir rekordgarsh)...
https://www.forbes.com/sites/johnlamattina/2017/03/15/turning-pfizer-discards-into-novartis-gold-the-story-of-ziarco/ |
|